Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_47_библиотеки_им_акад_М_И_Перельмана
.pdf
243
30. Kumar M, Jung SY, Hodgson AJ, Madden CR, Qin J, Slagle BL.Hepatitis B virus regulatory
HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J
Virol. 2011 Jan;85(2):987–95.
31. Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ.MAVS forms functional prion-like
aggregates to activate and propagate antiviral innate immune response. Cell. 2011 Aug
5;146(3):448–61.
32. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, etal. Hepatitis B virus suppresses
toll-like receptor-mediated innate immune responses in murine parenchymal and nonparen-
chymal liver cells. Hepatology. 2009 Apr;49(4):1132–40.
33. Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, et al.
Regulation of toll-like receptor-2 expression in chronic hepatitis B by the precore protein.
Hepatology. 2007 Jan;45(1):102–10.
34. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, etal. Incubation phase
of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology. 2000
Nov;32(5):1117–24.
35. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, etal. Early kinetics of innate and
adaptive immune responses during hepatitis B virus infection. Gut. 2009 Jul;58(7):974–82.
36. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L.NKT cells: what’s in a
name? Nat Rev Immunol. 2004 Mar;4(3):231–7.
37. Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, etal. Cellular immune
response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infec-
tion. J Immunol. 1990 Nov 15;145(10):3442–9.
38. Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, etal. Circulating and liver resident CD4+CD25+
regulatory T cells actively inuence the antiviral immune response and disease progression
in patients with hepatitis B.J Immunol. 2006 Jul 1;177(1):739–47.
39. Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE, Purcell RH, etal. The size
of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol. 2009
Oct;83(19):9652–62.
40. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, etal. The role of virus-specic
CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J
Exp Med. 2000 Apr 17;191(8):1269–80.
41. Thursz MR, Kwiatkowski D, Allsopp CE, Greenwood BM, Thomas HC, Hill AV.Association
between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J
Med. 1995 Apr 20;332(16):1065–9.
42. Hohler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, etal. HLA-DRB1*1301 and
*1302 protect against chronic hepatitis B.J Hepatol. 1997 Mar;26(3):503–7.
43. Ahn SH, Han KH, Park JY, Lee CK, Kang SW, Chon CY, etal. Association between hepatitis
B virus infection and HLA-DR type in Korea. Hepatology. 2000 Jun;31(6):1371–3.
44. Almarri A, Batchelor JR. HLA and hepatitis B infection. Lancet. 1994 Oct
29;344(8931):1194–5.
45. Jiang YG, Wang YM, Liu TH, Liu J.Association between HLA class II gene and susceptibil-
ity or resistance to chronic hepatitis B.World J Gastroenterol WJG. 2003 Oct;9(10):2221–5.
46. Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenefelde KH, Rittner C.A
tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic
hepatitis B infection. Clin Exp Immunol. 1998 Mar;111(3):579–82.
47. Kim YJ, Lee HS, Yoon JH, Kim CY, Park MH, Kim LH, etal. Association of TNF-alpha
promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet.
2003 Oct 1;12(19):2541–6.
48. Du T, Guo XH, Zhu XL, Li JH, Lu LP, Gao JR, et al. Association of TNF-alpha promoter
polymorphisms with the outcomes of hepatitis B virus infection in Chinese Han population.
J Viral Hepat. 2006 Sep;13(9):618–24.
7
Chronic Hepatitis B
https://t.me/medicina_free
244
49. Somi MH, Naja L, Noori BN, Alizadeh AH, Aghah MR, Shavakhi A, etal. Tumor necrosis
factor-alpha gene promoter polymorphism in Iranian patients with chronic hepatitis B.Indian
J Gastroenterol. 2006 Jan–Feb;25(1):14–5.
50. Xu J, Zhang S, Zhang Z, Fu L, Zheng Q, Wang J, et al. TNF-alpha promoter region poly-
morphisms affect HBV virus clearance in southern Chinese. Clin Chim Acta. 2013 Oct
21;425:90–2.
51. Xia Q, Zhou L, Liu D, Chen Z, Chen F. Relationship between TNF-α gene promoter
polymorphisms and outcomes of hepatitis B virus infections: a meta-analysis. PLoS One.
2011;6(5):e19606.
52. Frodsham AJ, Zhang L, Dumpis U, Taib NA, Best S, Durham A, etal. Class II cytokine
receptor gene cluster is a major locus for hepatitis B persistence. Proc Natl Acad Sci U S
A. 2006 June 13;103(24):9148–53.
53. Nishida N, Sawai H, Matsuura K, Sugiyama M, Ahn SH, Park JY, etal. Genome-wide asso-
ciation study conrming association of HLA-DP with protection against chronic hepatitis B
and viral clearance in Japanese and Korean. PLoS One. 2012;7(6):e39175.
54. Norder H, Hammas B, Lee SD, Bile K, Couroucé AM, Mushahwar IK, etal. Genetic related-
ness of hepatitis B viral strains of diverse geographical origin and natural variations in the
primary structure of the surface antigen. J Gen Virol. 1993 July;74(Pt 7):1341–8.
55. Ozasa A, Tanaka Y, Orito E, Sugiyama M, Kang JH, Hige S, et al. Inuence of genotypes
and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection.
Hepatology. 2006 Aug;44(2):326–34.
56. Suzuki Y, Kobayashi M, Ikeda K, Suzuki F, Arfase Y, Akuta N, et al. Persistence of acute
infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol. 2005
May;76(1):33–9.
57. Ito K, Yotsuyanagi H, Yatsuhashi H, Karino Y, Takikawa Y, Saito T, etal. Risk factors for
long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus
infection in Japanese adults. Hepatology. 2014 Jan;59(1):89–97.
58. Lin CL, Kao JH.The clinical implications of hepatitis B virus genotype: recent advances. J
Gastroenterol Hepatol. 2011 Jan;26(Suppl 1):123–30.
59. Sarkar N, Pal A, Das D, Saha D, Biswas A, Bandopadhayay B, etal. Virological character-
istics of acute hepatitis B in Eastern India: critical differences with chronic infection. PLoS
One. 2015;10(11):e0141741.
60. van Houdt R, Bruisten SM, Speksnijder AG, Prins M.Unexpectedly high proportion of drug
users and men having sex with men who develop chronic hepatitis B infection. J Hepatol.
2012 Sep;57(3):529–33.
61. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, etal. A
genome-wide association study identies variants in the HLA-DP locus associated with
chronic hepatitis B in Asians. Nat Genet. 2009 May;41(5):591–5.
62. Kim YJ, Kim HY, Lee JH, Yu SJ, Yoon JH, Lee HS, etal. A genome-wide association study
identied new variants associated with the risk of chronic hepatitis B.Hum Mol Genet. 2013
Oct 15;22(20):4233–8.
63. Hu Z, Liu Y, Zhai X, Dai J, Jin G, Wang L, etal. New loci associated with chronic hepatitis
B virus infection in Han Chinese. Nat Genet. 2013 Dec;45(12):1499–503.
64. Thio CL, Mosbruger T, Astemborski J, Greer S, Kirk GD, O’Brien SJ, et al. Mannose
binding lectin genotypes inuence recovery from hepatitis B virus infection. J Virol. 2005
Jul;79(14):9192–6.
65. http://www.cdc.gov/hepatitis/Statistics/SurveillanceGuidelines.htm. Division of Viral
Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
2018.
66. Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, et al.
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology
Commission. Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135–84.
N. V. Bergasa
https://t.me/medicina_free
245
67. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements
for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016
Dec;16(12):1399–408.
68. Hollinger BF, Purcell RH, Gerin JL, Ganem DE, Feinstone SM, Emerson SU, Major ME,
Schneider RJ, Lian TJ, Casey JL, Rehermann B.Hepatitis B.Viral Hepatitis. Philadelphia:
Lippincott Williams & Wilkins; 2002. p.103–68.
69. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, etal. Hepatitis B virus-
associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in
115 patients. Medicine. 2005 Sep;84(5):313–22.
70. Johnson RJ, Couser WG.Hepatitis B infection and renal disease: clinical, immunopathoge-
netic and therapeutic considerations. Kidney Int. 1990 Feb;37(2):663–76.
71. Lai KN, Li PK, Lui SF, Au TC, Tam JS, Tong KL, etal. Membranous nephropathy related to
hepatitis B virus in adults. N Engl J Med. 1991 May 23;324(21):1457–63.
72. Li SJ, Xu ST, Chen HP, Zhang MC, Xu F, Cheng SQ, etal. Clinical and morphologic spec-
trum of renal involvement in patients with HBV-associated cryoglobulinaemia. Nephrology
(Carlton, VIC). 2017 June;22(6):449–55.
73. Tabor E.Guillain-Barré syndrome and other neurologic syndromes in hepatitis A, B, and
non-A, non-B.J Med Virol. 1987 Mar;21(3):207–16.
74. Stübgen JP. Neuromuscular disorders associated with hepatitis B virus infection. J Clin
Neuromuscul Dis. 2011 Sep;13(1):26–37.
75. Bao SP. Association between hepatitis B and hearing status. Eur Rev Med Pharmacol Sci.
2017 Mar;21(5):922–7.
76. Bertoletti A, Kennedy PT.The immune tolerant phase of chronic HBV infection: new per-
spectives on an old concept. Cell Mol Immunol. 2015 May;12(3):258–63.
77. Lok AS, McMahon BJ, Practice Guidelines Committee AAftSoLD. Chronic hepatitis B:
update of recommendations. Hepatology. 2004 Mar;39(3):857–61.
78. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS.Management of hepatitis B: summary
of a clinical research workshop. Hepatology. 2007 Apr;45(4):1056–75.
79. Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, et al.
Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C,
D, and F.Gastroenterology. 2007 Nov;133(5):1452–7.
80. Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, etal. Sustained disease remission after
spontaneous HBeAg seroconversion is associated with reduction in brosis progression in
chronic hepatitis B Chinese patients. Hepatology. 2007 Sep;46(3):690–8.
81. Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS. Clinical and histo-
logical events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis.
Gastroenterology. 1983 Feb;84(2):216–9.
82. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, etal. Prospective study of hepatocel-
lular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J
Epidemiol. 1997 June 1;145(11):1039–47.
83. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS.Spontaneous hepatitis B e antigen to antibody
seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection.
Gastroenterology. 1987 Jun;92(6):1839–43.
84. de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, etal. The natu-
ral history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993 Feb
1;118(3):191–4.
85. Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, etal. Serum
hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol. 2002
Apr;36(4):543–6.
86. Zacharakis GH, Koskinas J, Kotsiou S, Papoutselis M, Tzara F, Vafeiadis N, etal. Natural his-
tory of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece
(part of the Interreg I-II/EC-project). J Med Virol. 2005 Oct;77(2):173–9.
7
Chronic Hepatitis B
https://t.me/medicina_free
246
87. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, etal. Virologic and histologic
features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal
ALT.Gastroenterology. 2008 May;134(5):1376–84.
88. Saab S, Dong MH, Joseph TA, Tong MJ.Hepatitis B prophylaxis in patients undergoing che-
motherapy for lymphoma: a decision analysis model. Hepatology. 2007 Oct;46(4):1049–56.
89. Perrillo RP.Acute ares in chronic hepatitis B: the natural and unnatural history of an immu-
nologically mediated liver disease. Gastroenterology. 2001 Mar;120(4):1009–22.
90. Chang ML, Liaw YF.Hepatitis B ares in chronic hepatitis B: pathogenesis, natural course,
and management. J Hepatol. 2014 Dec;61(6):1407–17.
91. Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, etal. Lamivudine prophylaxis reduces
the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy
for lymphoma. Cancer. 2006 Mar 15;106(6):1320–5.
92. Idilman R, Arat M, Soydan E, Toruner M, Soykan I, Akbulut H, etal. Lamivudine prophy-
laxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B
virus carriers with malignancies. J Viral Hepat. 2004 Mar;11(2):141–7.
93. Hwang JP, Suarez-Almazor ME, Cantor SB, Barbo A, Lin HY, Ahmed S, etal. Impact of
the timing of hepatitis B virus identication and anti-hepatitis B virus therapy initiation on
the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer. 2017 Sep
1;123(17):3367–76.
94. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B,
Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka JL, Straus SE, Hoofnagle JH. Hepatic
failure and lactic acidosis due to aluridine (FIAU), an investigational nucleoside analogue
for chronic hepatitis B.N Engl J Med. 1995;333:1099–105.
95. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, etal. Histological grading and
staging of chronic hepatitis. J Hepatol. 1995 Jun;22(6):696–9.
96. Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, et al. Acute exacerbations of
chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core
and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest. 1992
Jan;89(1):87–96.
97. Takehara T, Hayashi N, Katayama K, Kasahara A, Fusamoto H, Kamada T. Hepatitis
B core antigen-specic interferon gamma production of peripheral blood mononuclear
cells during acute exacerbation of chronic hepatitis B. Scand J Gastroenterol. 1992
Sep;27(9):727–31.
98. Fukuda R, Ishimura N, Nguyen TX, Chowdhury A, Ishihara S, Kohge N, etal. The expres-
sion of IL-2, IL-4 and interferon-gamma (IFN-gamma) mRNA using liver biopsies at
different phases of acute exacerbation of chronic hepatitis B. Clin Exp Immunol. 1995
Jun;100(3):446–51.
99. Feng IC, Koay LB, Sheu MJ, Kuo HT, Sun CS, Lee C, etal. HBcAg-specic CD4+CD25+
regulatory T cells modulate immune tolerance and acute exacerbation on the natural history
of chronic hepatitis B virus infection. J Biomed Sci. 2007 Jan;14(1):43–57.
100. Tan AT, Koh S, Goh W, Zhe HY, Gehring AJ, Lim SG, etal. A longitudinal analysis of innate
and adaptive immune prole during hepatic ares in chronic hepatitis B.J Hepatol. 2010
Mar;52(3):330–9.
101. Wenjin Z, Chuanhui P, Yunle W, Lateef SA, Shusen Z. Longitudinal uctuations in PD1
and PD-L1 expression in association with changes in anti-viral immune response in chronic
hepatitis B.BMC Gastroenterol. 2012 Aug 16;12:109.
102. Hoofnagle JH, Gerety RJ, Barker LF. Antibody to hepatitis-B-virus core in man. Lancet.
1973 Oct 20;2(7834):869–73.
103. Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol
J. 2013;10:239.
104. Hoofnagle JH, Ponzetto A, Mathiesen LR, Waggoner JG, Bales ZB, Seeff LB.Serological
diagnosis of acute viral hepatitis. Dig Dis Sci. 1985 Nov;30(11):1022–7.
105. http://www.cdc.gov/hepatitis/Statistics/SurveillanceGuidelines.htm. 2014.
N. V. Bergasa
https://t.me/medicina_free
247
106. Scheuer PF.Pathology of the liver. In: RNM MS, Anthony PP, Scheuer PJ, Burt AD, Portmann
BC, editors. Pathology of the liver. Edinburgh: Churchill Livingston; 1994. p.243–67.
107. Bianchi L, Gudat F.Chronic hepatitis. In: MacSween RNM, Anthony PP, Scheuer PJ, Burt
AD, Portmann BC, editors. Pathology of the liver. Edinburgh: Churchill Livingston; 1994.
p.349–95.
108. Anthony PP, Vogel CL, Barker LF.Liver cell dysplasia: a premalignant condition. J Clin
Pathol. 1973 Mar;26(3):217–23.
109. McMahon BJ, Holck P, Bulkow L, Snowball M.Serologic and clinical outcomes of 1536
Alaska natives chronically infected with hepatitis B virus. Ann Intern Med. 2001 Nov
6;135(9):759–68.
110. Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, etal. HBsAg seroclearance in chronic
hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology. 2004
Jun;39(6):1694–701.
111. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, etal. Risk of hepatocellular carcinoma across
a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006 Jan 4;295(1):65–73.
112. McMahon BJ.The natural history of chronic hepatitis B virus infection. Hepatology. 2009
May;49(5 Suppl):S45–55.
113. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J.Inuence of hepatitis B virus gen-
otype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology.
2002 Dec;123(6):1848–56.
114. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, etal. Hepatitis B virus genotype and
DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst.
2005 Feb 16;97(4):265–72.
115. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, etal. Associations between hepatitis B
virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008
Aug 20;100(16):1134–43.
116. Livingston SE, Simonetti JP, McMahon BJ, Bulkow LR, Hurlburt KJ, Homan CE, et al.
Hepatitis B virus genotypes in Alaska native people with hepatocellular carcinoma: prepon-
derance of genotype F.J Infect Dis. 2007 Jan 1;195(1):5–11.
117. Mahmoud D, Yerragorla P, Shady A, Shamian B, Bergasa NV. Characteristics of patient with
chronic hepatitis b from a community hospital in North Brooklyn. Gastroenterol Hepatol
Endosc 3: 2018. https://doi.org/10.15761/GHE.1000148.
118. Eloy AM, Moreira RC, Lemos MF, Silva JL, Coêlho MR.Hepatitis B virus in the state of
Alagoas, Brazil: genotypes characterization and mutations of the precore and basal core pro-
moter regions. Braz J Infect Dis. 2013 Nov–Dec;17(6):704–6.
119. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term
follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.N
Engl J Med. 1996 May 30;334(22):1422–7.
120. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M.Survival
and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver.
Gastroenterology. 1992 Nov;103(5):1630–5.
121. Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, Martorana G, etal. The long-
term course of chronic hepatitis B.Hepatology. 1999 Jul;30(1):257–64.
122. Tokudome S, Ikeda M, Matsushita K, Maeda Y, Yoshinari M.Hepatocellular carcinoma among
female Japanese hepatitis B virus carriers. Hepato-Gastroenterology. 1987 Dec;34(6):246–8.
123. Liaw YF, Lin DY, Chen TJ, Chu CM.Natural course after the development of cirrhosis in
patients with chronic type B hepatitis: a prospective study. Liver. 1989 Aug;9(4):235–41.
124. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J, et al.
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a mul-
ticenter study. The investigators of the European Concerted Action on Viral Hepatitis
(EUROHEP). J Hepatol. 1994 Oct;21(4):656–66.
125. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, etal. Natural history and
prognostic factors for chronic hepatitis type B.Gut. 1991 Mar;32(3):294–8.
7
Chronic Hepatitis B
https://t.me/medicina_free
248
126. Kew MC, Yu MC, Kedda MA, Coppin A, Sarkin A, Hodkinson J.The relative roles of hepa-
titis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks.
Gastroenterology. 1997 Jan;112(1):184–7.
127. Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, etal. The Gambia Liver Cancer
Study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West
Africa. Hepatology. 2004 Jan;39(1):211–9.
128. Liaw YF, Tsai SL, Chang JJ, Sheen IS, Chien RN, Lin DY, etal. Displacement of hepatitis B
virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology. 1994
Apr;106(4):1048–53.
129. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM.Impact of acute hepatitis C virus
superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004
Apr;126(4):1024–9.
130. Donato F, Boffetta P, Puoti M.A meta-analysis of epidemiological studies on the combined
effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer.
1998 Jan 30;75(3):347–54.
131. Chu CM, Yeh CT, Liaw YF.Fulminant hepatic failure in acute hepatitis C: increased risk in
chronic carriers of hepatitis B virus. Gut. 1999 Oct;45(4):613–7.
132. Le Gal F, Brichler S, Drugan T, Alloui C, Roulot D, Pawlotsky JM, et al. Genetic diver-
sity and worldwide distribution of the deltavirus genus: a study of 2,152 clinical strains.
Hepatology. 2017 Dec;66(6):1826–41.
133. Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, etal. Genotypes and viremia
of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients.
Gastroenterology. 2006 May;130(6):1625–35.
134. Pasetti G, Calzetti C, Degli Antoni A, Ferrari C, Penna A, Fiaccadori F.Clinical features of
hepatitis delta virus infection in a northern Italian area. Infection. 1988;16(6):345–8.
135. Raimondo G, Smedile A, Gallo L, Balbo A, Ponzetto A, Rizzetto M.Multicentre study of
prevalence of HBV-associated delta infection and liver disease in drug-addicts. Lancet. 1982
Jan 30;1(8266):249–51.
136. Negro F. Hepatitis D virus coinfection and superinfection. Cold Spring Harb Perspect Med.
2014;4(11):a021550.
137. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Inuence
of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type
B.The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000 Mar;46(3):420–6.
138. Popper H, Thung SN, Gerber MA, Hadler SC, de Monzon M, Ponzetto A, et al.
Histologic studies of severe delta agent infection in Venezuelan Indians. Hepatology. 1983
Nov–Dec;3(6):906–12.
139. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis
B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet.
2002 Dec 14;360(9349):1921–6.
140. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on
the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370–98.
141. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, etal. Update on
prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guid-
ance. Hepatology. 2018 Apr;67(4):1560–99.
142. Hwang JP, Lok AS.Management of patients with hepatitis B who require immunosuppres-
sive therapy. Nat Rev Gastroenterol Hepatol. 2014 Apr;11(4):209–19.
143. Choi J, Lim YS.Characteristics, prevention, and management of Hepatitis B Virus (HBV)
reactivation in HBV-infected patients who require immunosuppressive therapy. J Infect Dis.
2017 Nov 16;216(suppl 8):S778–84.
144. Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, etal. Two sensi-
tive PCR-based methods for detection of hepatitis B virus variants associated with reduced
susceptibility to lamivudine. J Clin Microbiol. 1999 Oct;37(10):3338–47.
N. V. Bergasa
https://t.me/medicina_free
249
145. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B
exacerbations in human immunodeciency virus-infected patients following development of
resistance to or withdrawal of lamivudine. Clin Infect Dis. 1999 May;28(5):1032–5.
146. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors
that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to
peginterferon-alfa. Gastroenterology. 2009 Dec;137(6):2002–9.
147. Lee JM, Ahn SH, Kim HS, Park H, Chang HY, Kim DY, etal. Quantitative hepatitis B sur-
face antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.
Hepatology. 2011 May;53(5):1486–93.
148. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD
guidelines for treatment of chronic hepatitis B.Hepatology. 2016 Jan;63(1):261–83.
149. Chu CM, Liaw YF.Chronic hepatitis B virus infection acquired in childhood: special empha-
sis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral
Hepat. 2007 Mar;14(3):147–52.
150. Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, etal. Tenofovir to prevent hepatitis B
transmission in mothers with high viral load. N Engl J Med. 2016 Jun 16;374(24):2324–34.
151. Brown RS Jr, McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, etal. Antiviral
therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-
analysis. Hepatology. 2016 Jan;63(1):319–33.
152. Lampertico P, Maini M, Papatheodoridis G.Optimal management of hepatitis B virus infec-
tion- EASL special conference. J Hepatol. 2015 Nov;63(5):1238–53.
153. Vlachogiannakos J, Papatheodoridis GV.Hepatitis B: who and when to treat? Liver Int. 2018
Feb;38(Suppl 1):71–8.
154. Xu C, Guo H, Pan XB, Mao R, Yu W, Xu X, etal. Interferons accelerate decay of replication-
competent nucleocapsids of hepatitis B virus. J Virol. 2010 Sep;84(18):9332–40.
155. Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, etal. Differential boost-
ing of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of
chronic hepatitis B.J Hepatol. 2013 Feb;58(2):225–33.
156. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, etal. IFN-alpha inhib-
its HBV transcription and replication in cell culture and in humanized mice by targeting
the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012
Feb;122(2):529–37.
157. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, etal. Specic and nonhepatotoxic
degradation of nuclear hepatitis B virus cccDNA.Science. 2014 Mar 14;343(6176):1221–8.
158. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, etal. Rational design
of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-
conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem. 2001
Mar–Apr;12(2):195–202.
159. Perry CM, Jarvis B.Peginterferon-alpha-2a (40 kD): a review of its use in the management
of chronic hepatitis C.Drugs. 2001;61(15):2263–88.
160. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon
Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. The New
England journal of medicine. 2005;352(26):2682–95.
161. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-
2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative
chronic hepatitis B. The New England journal of medicine. 2004;351(12):1206–17.
162. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, etal. Formulation and
application of a numerical scoring system for assessing histological activity in asymptomatic
chronic active hepatitis. Hepatology. 1981 Sep–Oct;1(5):431–5.
163. Hui AY, Chan HL, Cheung AY, Cooksley G, Sung JJ.Systematic review: treatment of chronic
hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther. 2005 Sep
15;22(6):519–28.
7
Chronic Hepatitis B
https://t.me/medicina_free
250
164. Clark DN, Flanagan JM, Hu J.Mapping of functional subdomains in the terminal protein
domain of hepatitis B virus polymerase. J Virol. 2017 Feb;1:91(3).
165. Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of
chronic hepatitis B.J Antimicrob Chemother. 2011 Dec;66(12):2715–25.
166. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir diso-
proxil fumarate versus adefovir dipivoxil for chronic hepatitis B. The New England journal
of medicine. 2008;359(23):2442–55.
167. Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, etal. Tenofovir alafenamide
versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative
chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196–206.
168. Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, etal. Tenofovir alafenamide
versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepati-
tis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet
Gastroenterol Hepatol. 2016 Nov;1(3):185–95.
169. Kim V, Abreu RM, Nakagawa DM, Baldassare RM, Carrilho FJ, Ono SK.Pegylated inter-
feron alfa for chronic hepatitis B: systematic review and meta-analysis. J Viral Hepat. 2016
Mar;23(3):154–69.
170. Matthews SJ.Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther.
2006;28(2):184–203.
171. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, et al. Tenofovir disoproxil
fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: a 5-year
randomised study. J Hepatol. 2017 Jan;66(1):11–8.
172. Peng H, Liu J, Yang M, Tong S, Yin W, Tang H, et al. Efcacy of lamivudine combined
with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated
decompensated cirrhosis: a meta-analysis. J Clin Pharmacol. 2014 Feb;54(2):189–200.
173. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, etal. Entecavir treatment for
up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.Hepatology.
2010 Feb;51(2):422–30.
174. Chi H, Hansen BE, Guo S, Zhang NP, Qi X, Chen L, etal. Pegylated interferon alfa-2b add-
on treatment in hepatitis B virus envelope antigen-positive chronic hepatitis B patients treated
with Nucleos(t)ide analogue: a randomized, controlled trial (PEGON). J Infect Dis. 2017 Apr
1;215(7):1085–93.
175. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, etal. Long-term
monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare
through 5 years of therapy. Hepatology. 2009 May;49(5):1503–14.
176. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E.Sustained responses
and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term
treatment with adefovir. Gastroenterology. 2012 Sep;143(3):629–36.
177. Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, etal. Long-term response after
stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients- FINITE
study. J Hepatol. 2017 Nov;67(5):918–24.
178. Jeng WJ, Chen YC, Chien RN, Sheen IS, Liaw YF.Incidence and predictors of hepatitis B
surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B
e antigen-negative chronic hepatitis B.Hepatology. 2018 Aug;68(2):425–34.
179. Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, et al. Serum hepatitis B sur-
face antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.
Gastroenterology. 2011 Aug;141(2):517–25.e1-2.
180. Dusheiko G.Current and future directions for the management of hepatitis B.South Afr Med
J. 2018 Aug 8;108(8b):22–30.
181. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, et al. Pegylated inter-
feron alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.
Hepatology. 2006 Sep;44(3):713–20.
N. V. Bergasa
https://t.me/medicina_free
251
182. Gheorghe L, Iacob S, Simionov I, Vadan R, Constantinescu I, Caruntu F, et al. Weight-
based dosing regimen of peg-interferon alpha-2b for chronic hepatitis delta: a multicenter
Romanian trial. J Gastrointestin Liver Dis JGLD. 2011 Dec;20(4):377–82.
183. Yurdaydin C, Tabak F, Kaymakoglu S, Akarsu M, Akinci EG, Akkiz H, et al. Diagnosis,
management and treatment of hepatitis delta virus infection: Turkey 2017 clinical practice
guidelines. Turk J Gastroenterol. 2017 Dec;28(Suppl 2):84–9.
184. Yurdaydin C, Keskin O, Kalkan C, Karakaya F, Caliskan A, Kabacam G, et al. Interferon
treatment duration in patients with chronic delta hepatitis and its effect on the natural course
of the disease. J Infect Dis. 2018 Mar 28;217(8):1184–92.
185. Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, etal. First-in-human application
of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B.J Hepatol. 2016
Sep;65(3):483–9.
186. Yurdaydin C, Keskin O, Kalkan C, Karakaya F, Caliskan A, Karatayli E, etal. Optimizing
lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
Hepatology. 2018 Apr;67(4):1224–36.
187. Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, etal. Safety and ef-
cacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic
hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-
randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2017 Dec;2(12):877–89.
188. Hamid SS, Etzion O, Lurie Y, Bader N, Yardeni D, Channa SM, Mawani M, Parkash O,
Martins, EB, Gane EJ.A phase 2 randomized clinical trial to evaluate the safety and efcacy
of pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus
infection: interim results from the LIMT HDV Study. Hepatology. 2017, Abstract #927.
189. Reddy KR, Ellerbe C, Schilsky M, Stravitz RT, Fontana RJ, Durkalski V, etal. Determinants
of outcome among patients with acute liver failure listed for liver transplantation in the
United States. Liver Transpl. 2016 Apr;22(4):505–15.
190. Young K, Liu B, Bhuket T, Younossi Z, Saab S, Ahmed A, etal. Long-term trends in chronic
hepatitis B virus infection associated liver transplantation outcomes in the United States. J
Viral Hepat. 2017 Sep;24(9):789–96.
191. Burra P, Germani G, Adam R, Karam V, Marzano A, Lampertico P, etal. Liver transplantation
for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol.
2013 Feb;58(2):287–96.
192. Cholongitas E, Papatheodoridis GV.High genetic barrier nucleos(t)ide analogue(s) for pro-
phylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am
J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2013 Feb;13(2):353–62.
193. Lima DS, Murad Junior AJ, Barreira MA, Fernandes GC, Coelho GR, Garcia JHP.Liver
transplantation in Hepatitis Delta: South America experience. Arq Gastroenterol. 2018
Jan–Mar;55(1):14–7.
194. Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, David MF, etal. Long-term clini-
cal and virological outcome after liver transplantation for cirrhosis caused by chronic delta
hepatitis. Hepatology. 1995 Feb;21(2):333–9.
195. Roche B, Samuel D.Liver transplantation in delta virus infection. Semin Liver Dis. 2012
Aug;32(3):245–55.
196. Fox AN, Terrault NA.The option of HBIG-free prophylaxis against recurrent HBV.J Hepatol.
2012 May;56(5):1189–97.
197. Fung J.Management of chronic hepatitis B before and after liver transplantation. World J
Hepatol. 2015 Jun 8;7(10):1421–6.
198. de The H, Tiollais P, Dejean A. Hepatitis B virus and hepatocarcinoma: integration of
HBV DNA in the gene coding for the receptor of retinoic acid. Pathologie-Biologie. 1989
Jan;37(1):5–6.
199. Wang J, Chenivesse X, Henglein B, Brechot C.Hepatitis B virus integration in a cyclin A
gene in a hepatocellular carcinoma. Nature. 1990 Feb 8;343(6258):555–7.
7
Chronic Hepatitis B
https://t.me/medicina_free
252
200. Graef E, Caselmann WH, Wells J, Koshy R.Insertional activation of mevalonate kinase by
hepatitis B virus DNA in a human hepatoma cell line. Oncogene. 1994 Jan;9(1):81–7.
201. Ferber MJ, Montoya DP, Yu C, Aderca I, McGee A, Thorland EC, et al. Integrations of
the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomer-
ase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene. 2003 Jun
12;22(24):3813–20.
202. Horikawa I, Barrett JC.Transcriptional regulation of the telomerase hTERT gene as a target
for cellular and viral oncogenic mechanisms. Carcinogenesis. 2003 Jul;24(7):1167–76.
203. Paterlini-Brechot P, Saigo K, Murakami Y, Chami M, Gozuacik D, Mugnier C, etal. Hepatitis
B virus-related insertional mutagenesis occurs frequently in human liver cancers and recur-
rently targets human telomerase gene. Oncogene. 2003 June 19;22(25):3911–6.
204. Feitelson MA, Zhu M, Duan LX, London WT.Hepatitis B x antigen and p53 are associated
invitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene.
1993 May;8(5):1109–17.
205. Kim SS, Cho HJ, Lee HY, Park JH, Noh CK, Shin SJ, et al. Genetic polymorphisms in
the Wnt/beta-catenin pathway genes as predictors of tumor development and survival in
patients with hepatitis B virus-associated hepatocellular carcinoma. Clin Biochem. 2016
Jul;49(10–11):792–801.
206. Peng CY, Chen TC, Hung SP, Chen MF, Yeh CT, Tsai SL, et al. Genetic alterations of
INK4alpha/ARF locus and p53in human hepatocellular carcinoma. Anticancer Res. 2002
Mar–Apr;22(2B):1265–71.
207. Liu N, Jiao T, Huang Y, Liu W, Li Z, Ye X.Hepatitis B virus regulates apoptosis and tumori-
genesis through the microRNA-15a-Smad7-transforming growth factor beta pathway. J Virol.
2015 Mar;89(5):2739–49.
208. Wang F, Anderson PW, Salem N, Kuang Y, Tennant BC, Lee Z. Gene expression studies
of hepatitis virus-induced woodchuck hepatocellular carcinoma in correlation with human
results. Int J Oncol. 2007 Jan;30(1):33–44.
209. Ha HL, Yu DY. HBx-induced reactive oxygen species activates hepatocellular carcino-
genesis via dysregulation of PTEN/Akt pathway. World J Gastroenterol WJG. 2010 Oct
21;16(39):4932–7.
210. Xie Q, Su Y, Dykema K, Johnson J, Koeman J, De Giorgi V, etal. Overexpression of HGF
promotes HBV-induced hepatocellular carcinoma progression and is an effective Indicator
for met-targeting therapy. Genes Cancer. 2013 Jul;4(7–8):247–60.
211. Kim SO, Park JG, Lee YI. Increased expression of the insulin-like growth factor I (IGF-I)
receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene
activation by hepatitis B virus X gene product. Cancer Res. 1996 Aug 15;56(16):3831–6.
212. Sarkar D.AEG-1/MTDH/LYRIC in liver cancer. Adv Cancer Res. 2013;120:193–221.
213. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, etal. Genetic alterations
associated with hepatocellular carcinomas dene distinct pathways of hepatocarcinogenesis.
Gastroenterology. 2001 Jun;120(7):1763–73.
214. Marchio A, Pineau P, Meddeb M, Terris B, Tiollais P, Bernheim A, etal. Distinct chromo-
somal abnormality pattern in primary liver cancer of non-B, non-C patients. Oncogene. 2000
Aug 3;19(33):3733–8.
215. Zhang H, Zhai Y, Hu Z, Wu C, Qian J, Jia W, etal. Genome-wide association study identies
1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B
virus carriers. Nat Genet. 2010 Sep;42(9):755–8.
216. Hakami A, Ali A, Hakami A.Effects of hepatitis B virus mutations on its replication and liver
disease severity. Open Virol J. 2013;7:12–8.
217. Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, etal. Nomograms for risk of hepa-
tocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010
May 10;28(14):2437–44.
218. Kew MC, Macerollo P.Effect of age on the etiologic role of the hepatitis B virus in hepatocel-
lular carcinoma in blacks. Gastroenterology. 1988 Feb;94(2):439–42.
N. V. Bergasa
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана